New CEO appointed
The board of PharmNovo AB is pleased to announce that former VP Business Development Per von Mentzer assumed the position as new Chief Executive Officer of PharmNovo AB effective May 2020.
“Given his general management and commercial experience, we are confident that Per is the right person to lead us through the next phases of development,” says Chairman of the Board Göran Lerenius, who continues:
“Through this appointment PharmNovo is strengthening the organisation on both the scientific and commercial sides, whilst maintaining full focus on the continued pre-clinical development.
The company’s founder and former CEO, Bengt von Mentzer, remains critical to PharmNovo´s business activities and will now focus even more of his time and efforts on the PN6047 development and the upcoming Regulatory Toxicology programme.
At the Extraordinary General Meeting held in May at Medicon Village, Lund, Sweden, Chairman of the Board Göran Lerenius thanked Bengt for founding the company and for leading it successfully over many years.
New CEO appointed
The board of PharmNovo AB is pleased to announce that former VP Business Development Per von Mentzer assumed the position as new Chief Executive Officer of PharmNovo AB effective May 2020.
“Given his general management and commercial experience, we are confident that Per is the right person to lead us through the next phases of development,” says Chairman of the Board Göran Lerenius, who continues:
“Through this appointment PharmNovo is strengthening the organisation on both the scientific and commercial sides, whilst maintaining full focus on the continued pre-clinical development.
The company’s founder and former CEO, Bengt von Mentzer, remains critical to PharmNovo´s business activities and will now focus even more of his time and efforts on the PN6047 development and the upcoming Regulatory Toxicology programme.
At the Extraordinary General Meeting held in May at Medicon Village, Lund, Sweden, Chairman of the Board Göran Lerenius thanked Bengt for founding the company and for leading it successfully over many years.
Latest news
View all
Positive final Phase I results
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read more
Meet Bengt von Mentzer, founder and Chief scientific advisor
Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more
NIDA funds studies
The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
Read more
Meet Olof Breuer, MD, Clinical pharmacology lead
Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.
Read more